Skip to main content
. 2017 Jul 10;127(8):3028–3038. doi: 10.1172/JCI92707

Figure 5. Topical and intradermal gentamicin do not induce anti–type VII collagen antibodies.

Figure 5

(A) Sera were obtained from RDEB patients before and 1 month after receiving gentamicin treatments and subjected to an ELISA using a commercially available ELISA kit against type VII collagen. Note that low-level anti–type VII collagen IgG antibodies were detected in 2 of the RDEB patients at day 0. However, none of the patients’ sera exhibited any increases in anti–type VII collagen IgG antibodies at 1 month after gentamicin treatment. Serum from a patient with EBA was used as a positive control, while serum from a normal human subject (NHS) was used as a negative control. Data represent the mean ± SD. (B) Skin biopsies from the gentamicin-treated test sites were obtained 1 month and 3 months after treatment and subjected to direct IF using an FITC-conjugated goat anti-human IgG antibody. Note that no IgG deposits of human anti–type VII collagen IgG were detected in any of the test sites. Scale bar: 50 μm.